Research ArticleArticle
Behçet Syndrome Manifestations and Activity in the United States versus Turkey — A Cross-sectional Cohort Comparison
Cailin Sibley, Yusuf Yazici, Koray Tascilar, Nafiz Khan, Yasmin Bata, Hasan Yazici, Raphaela Goldbach-Mansky and Gulen Hatemi
The Journal of Rheumatology June 2014, jrheum.131227; DOI: https://doi.org/10.3899/jrheum.131227
Cailin Sibley
From the Translational Autoinflammatory Disease Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases at the National Institutes of Health, Bethesda, Maryland; Department of Rheumatology, Oregon Health and Science University, Portland, Oregon; Department of Rheumatology, New York University, New York, New York, USA; Department of Rheumatology, University of Istanbul Cerrahpasa, Istanbul, Turkey. Supported by the Intramural Research Program of the US National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) at the National Institutes of Health (NIH), New York University, and the University of Istanbul. Yusuf Yazici is a consultant for Abbvie, BMS, Celgene, Genentech, Pfizer, UCB, Horizon, and Medac; and holds research grants from BMS, Genentech, and Celgene. Raphaela Goldbach-Mansky has received grant support from Regeneron, Novartis, and BIovitrum Inc. C. Sibley, MD, MHS, Translational Autoinflammatory Disease Section, NIAMS at the NIH; and Department of Rheumatology, Oregon Health and Science University; Y. Yazici, MD, Department of Rheumatology, New York University; K. Tascilar, MD, Department of Rheumatology, University of Istanbul Cerrahpasa; N. Khan, BS, Translational Autoinflammatory Disease Section, NIAMS at the NIH; Y. Bata, BA, Department of Rheumatology, New York University; H. Yazici, MD, Department of Rheumatology, University of Istanbul Cerrahpasa; R. Goldbach-Mansky, MD, MHS, Translational Autoinflammatory Disease Section, NIAMS at the NIH; G. Hatemi, MD, Department of Rheumatology, University of Istanbul Cerrahpasa. Address correspondence to Dr. Sibley, Translational Autoinflammatory Disease Section, NIH/NIAMS, Building 10, Room 6N216-G, MSC 1616, 10 Center Drive, Bethesda, Maryland 20892, USA. E-mail: sibleych@mail.nih.gov. Accepted for publication March 26, 2014.
Yusuf Yazici
From the Translational Autoinflammatory Disease Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases at the National Institutes of Health, Bethesda, Maryland; Department of Rheumatology, Oregon Health and Science University, Portland, Oregon; Department of Rheumatology, New York University, New York, New York, USA; Department of Rheumatology, University of Istanbul Cerrahpasa, Istanbul, Turkey. Supported by the Intramural Research Program of the US National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) at the National Institutes of Health (NIH), New York University, and the University of Istanbul. Yusuf Yazici is a consultant for Abbvie, BMS, Celgene, Genentech, Pfizer, UCB, Horizon, and Medac; and holds research grants from BMS, Genentech, and Celgene. Raphaela Goldbach-Mansky has received grant support from Regeneron, Novartis, and BIovitrum Inc. C. Sibley, MD, MHS, Translational Autoinflammatory Disease Section, NIAMS at the NIH; and Department of Rheumatology, Oregon Health and Science University; Y. Yazici, MD, Department of Rheumatology, New York University; K. Tascilar, MD, Department of Rheumatology, University of Istanbul Cerrahpasa; N. Khan, BS, Translational Autoinflammatory Disease Section, NIAMS at the NIH; Y. Bata, BA, Department of Rheumatology, New York University; H. Yazici, MD, Department of Rheumatology, University of Istanbul Cerrahpasa; R. Goldbach-Mansky, MD, MHS, Translational Autoinflammatory Disease Section, NIAMS at the NIH; G. Hatemi, MD, Department of Rheumatology, University of Istanbul Cerrahpasa. Address correspondence to Dr. Sibley, Translational Autoinflammatory Disease Section, NIH/NIAMS, Building 10, Room 6N216-G, MSC 1616, 10 Center Drive, Bethesda, Maryland 20892, USA. E-mail: sibleych@mail.nih.gov. Accepted for publication March 26, 2014.
Koray Tascilar
From the Translational Autoinflammatory Disease Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases at the National Institutes of Health, Bethesda, Maryland; Department of Rheumatology, Oregon Health and Science University, Portland, Oregon; Department of Rheumatology, New York University, New York, New York, USA; Department of Rheumatology, University of Istanbul Cerrahpasa, Istanbul, Turkey. Supported by the Intramural Research Program of the US National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) at the National Institutes of Health (NIH), New York University, and the University of Istanbul. Yusuf Yazici is a consultant for Abbvie, BMS, Celgene, Genentech, Pfizer, UCB, Horizon, and Medac; and holds research grants from BMS, Genentech, and Celgene. Raphaela Goldbach-Mansky has received grant support from Regeneron, Novartis, and BIovitrum Inc. C. Sibley, MD, MHS, Translational Autoinflammatory Disease Section, NIAMS at the NIH; and Department of Rheumatology, Oregon Health and Science University; Y. Yazici, MD, Department of Rheumatology, New York University; K. Tascilar, MD, Department of Rheumatology, University of Istanbul Cerrahpasa; N. Khan, BS, Translational Autoinflammatory Disease Section, NIAMS at the NIH; Y. Bata, BA, Department of Rheumatology, New York University; H. Yazici, MD, Department of Rheumatology, University of Istanbul Cerrahpasa; R. Goldbach-Mansky, MD, MHS, Translational Autoinflammatory Disease Section, NIAMS at the NIH; G. Hatemi, MD, Department of Rheumatology, University of Istanbul Cerrahpasa. Address correspondence to Dr. Sibley, Translational Autoinflammatory Disease Section, NIH/NIAMS, Building 10, Room 6N216-G, MSC 1616, 10 Center Drive, Bethesda, Maryland 20892, USA. E-mail: sibleych@mail.nih.gov. Accepted for publication March 26, 2014.
Nafiz Khan
From the Translational Autoinflammatory Disease Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases at the National Institutes of Health, Bethesda, Maryland; Department of Rheumatology, Oregon Health and Science University, Portland, Oregon; Department of Rheumatology, New York University, New York, New York, USA; Department of Rheumatology, University of Istanbul Cerrahpasa, Istanbul, Turkey. Supported by the Intramural Research Program of the US National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) at the National Institutes of Health (NIH), New York University, and the University of Istanbul. Yusuf Yazici is a consultant for Abbvie, BMS, Celgene, Genentech, Pfizer, UCB, Horizon, and Medac; and holds research grants from BMS, Genentech, and Celgene. Raphaela Goldbach-Mansky has received grant support from Regeneron, Novartis, and BIovitrum Inc. C. Sibley, MD, MHS, Translational Autoinflammatory Disease Section, NIAMS at the NIH; and Department of Rheumatology, Oregon Health and Science University; Y. Yazici, MD, Department of Rheumatology, New York University; K. Tascilar, MD, Department of Rheumatology, University of Istanbul Cerrahpasa; N. Khan, BS, Translational Autoinflammatory Disease Section, NIAMS at the NIH; Y. Bata, BA, Department of Rheumatology, New York University; H. Yazici, MD, Department of Rheumatology, University of Istanbul Cerrahpasa; R. Goldbach-Mansky, MD, MHS, Translational Autoinflammatory Disease Section, NIAMS at the NIH; G. Hatemi, MD, Department of Rheumatology, University of Istanbul Cerrahpasa. Address correspondence to Dr. Sibley, Translational Autoinflammatory Disease Section, NIH/NIAMS, Building 10, Room 6N216-G, MSC 1616, 10 Center Drive, Bethesda, Maryland 20892, USA. E-mail: sibleych@mail.nih.gov. Accepted for publication March 26, 2014.
Yasmin Bata
From the Translational Autoinflammatory Disease Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases at the National Institutes of Health, Bethesda, Maryland; Department of Rheumatology, Oregon Health and Science University, Portland, Oregon; Department of Rheumatology, New York University, New York, New York, USA; Department of Rheumatology, University of Istanbul Cerrahpasa, Istanbul, Turkey. Supported by the Intramural Research Program of the US National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) at the National Institutes of Health (NIH), New York University, and the University of Istanbul. Yusuf Yazici is a consultant for Abbvie, BMS, Celgene, Genentech, Pfizer, UCB, Horizon, and Medac; and holds research grants from BMS, Genentech, and Celgene. Raphaela Goldbach-Mansky has received grant support from Regeneron, Novartis, and BIovitrum Inc. C. Sibley, MD, MHS, Translational Autoinflammatory Disease Section, NIAMS at the NIH; and Department of Rheumatology, Oregon Health and Science University; Y. Yazici, MD, Department of Rheumatology, New York University; K. Tascilar, MD, Department of Rheumatology, University of Istanbul Cerrahpasa; N. Khan, BS, Translational Autoinflammatory Disease Section, NIAMS at the NIH; Y. Bata, BA, Department of Rheumatology, New York University; H. Yazici, MD, Department of Rheumatology, University of Istanbul Cerrahpasa; R. Goldbach-Mansky, MD, MHS, Translational Autoinflammatory Disease Section, NIAMS at the NIH; G. Hatemi, MD, Department of Rheumatology, University of Istanbul Cerrahpasa. Address correspondence to Dr. Sibley, Translational Autoinflammatory Disease Section, NIH/NIAMS, Building 10, Room 6N216-G, MSC 1616, 10 Center Drive, Bethesda, Maryland 20892, USA. E-mail: sibleych@mail.nih.gov. Accepted for publication March 26, 2014.
Hasan Yazici
From the Translational Autoinflammatory Disease Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases at the National Institutes of Health, Bethesda, Maryland; Department of Rheumatology, Oregon Health and Science University, Portland, Oregon; Department of Rheumatology, New York University, New York, New York, USA; Department of Rheumatology, University of Istanbul Cerrahpasa, Istanbul, Turkey. Supported by the Intramural Research Program of the US National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) at the National Institutes of Health (NIH), New York University, and the University of Istanbul. Yusuf Yazici is a consultant for Abbvie, BMS, Celgene, Genentech, Pfizer, UCB, Horizon, and Medac; and holds research grants from BMS, Genentech, and Celgene. Raphaela Goldbach-Mansky has received grant support from Regeneron, Novartis, and BIovitrum Inc. C. Sibley, MD, MHS, Translational Autoinflammatory Disease Section, NIAMS at the NIH; and Department of Rheumatology, Oregon Health and Science University; Y. Yazici, MD, Department of Rheumatology, New York University; K. Tascilar, MD, Department of Rheumatology, University of Istanbul Cerrahpasa; N. Khan, BS, Translational Autoinflammatory Disease Section, NIAMS at the NIH; Y. Bata, BA, Department of Rheumatology, New York University; H. Yazici, MD, Department of Rheumatology, University of Istanbul Cerrahpasa; R. Goldbach-Mansky, MD, MHS, Translational Autoinflammatory Disease Section, NIAMS at the NIH; G. Hatemi, MD, Department of Rheumatology, University of Istanbul Cerrahpasa. Address correspondence to Dr. Sibley, Translational Autoinflammatory Disease Section, NIH/NIAMS, Building 10, Room 6N216-G, MSC 1616, 10 Center Drive, Bethesda, Maryland 20892, USA. E-mail: sibleych@mail.nih.gov. Accepted for publication March 26, 2014.
Raphaela Goldbach-Mansky
From the Translational Autoinflammatory Disease Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases at the National Institutes of Health, Bethesda, Maryland; Department of Rheumatology, Oregon Health and Science University, Portland, Oregon; Department of Rheumatology, New York University, New York, New York, USA; Department of Rheumatology, University of Istanbul Cerrahpasa, Istanbul, Turkey. Supported by the Intramural Research Program of the US National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) at the National Institutes of Health (NIH), New York University, and the University of Istanbul. Yusuf Yazici is a consultant for Abbvie, BMS, Celgene, Genentech, Pfizer, UCB, Horizon, and Medac; and holds research grants from BMS, Genentech, and Celgene. Raphaela Goldbach-Mansky has received grant support from Regeneron, Novartis, and BIovitrum Inc. C. Sibley, MD, MHS, Translational Autoinflammatory Disease Section, NIAMS at the NIH; and Department of Rheumatology, Oregon Health and Science University; Y. Yazici, MD, Department of Rheumatology, New York University; K. Tascilar, MD, Department of Rheumatology, University of Istanbul Cerrahpasa; N. Khan, BS, Translational Autoinflammatory Disease Section, NIAMS at the NIH; Y. Bata, BA, Department of Rheumatology, New York University; H. Yazici, MD, Department of Rheumatology, University of Istanbul Cerrahpasa; R. Goldbach-Mansky, MD, MHS, Translational Autoinflammatory Disease Section, NIAMS at the NIH; G. Hatemi, MD, Department of Rheumatology, University of Istanbul Cerrahpasa. Address correspondence to Dr. Sibley, Translational Autoinflammatory Disease Section, NIH/NIAMS, Building 10, Room 6N216-G, MSC 1616, 10 Center Drive, Bethesda, Maryland 20892, USA. E-mail: sibleych@mail.nih.gov. Accepted for publication March 26, 2014.
Gulen Hatemi
From the Translational Autoinflammatory Disease Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases at the National Institutes of Health, Bethesda, Maryland; Department of Rheumatology, Oregon Health and Science University, Portland, Oregon; Department of Rheumatology, New York University, New York, New York, USA; Department of Rheumatology, University of Istanbul Cerrahpasa, Istanbul, Turkey. Supported by the Intramural Research Program of the US National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) at the National Institutes of Health (NIH), New York University, and the University of Istanbul. Yusuf Yazici is a consultant for Abbvie, BMS, Celgene, Genentech, Pfizer, UCB, Horizon, and Medac; and holds research grants from BMS, Genentech, and Celgene. Raphaela Goldbach-Mansky has received grant support from Regeneron, Novartis, and BIovitrum Inc. C. Sibley, MD, MHS, Translational Autoinflammatory Disease Section, NIAMS at the NIH; and Department of Rheumatology, Oregon Health and Science University; Y. Yazici, MD, Department of Rheumatology, New York University; K. Tascilar, MD, Department of Rheumatology, University of Istanbul Cerrahpasa; N. Khan, BS, Translational Autoinflammatory Disease Section, NIAMS at the NIH; Y. Bata, BA, Department of Rheumatology, New York University; H. Yazici, MD, Department of Rheumatology, University of Istanbul Cerrahpasa; R. Goldbach-Mansky, MD, MHS, Translational Autoinflammatory Disease Section, NIAMS at the NIH; G. Hatemi, MD, Department of Rheumatology, University of Istanbul Cerrahpasa. Address correspondence to Dr. Sibley, Translational Autoinflammatory Disease Section, NIH/NIAMS, Building 10, Room 6N216-G, MSC 1616, 10 Center Drive, Bethesda, Maryland 20892, USA. E-mail: sibleych@mail.nih.gov. Accepted for publication March 26, 2014.
Published eLetters
eLetters are comments published online only and are not peer-reviewed. Publication of eLetter submissions is not guaranteed, and all submissions are reviewed and edited at the discretion of The Journal's staff.
If you wish to publish Letters to the Editor or Correspondence, please submit through our online submission system ScholarOne Manuscripts.
Jump to comment:
No eLetters have been published for this article.
In this issue
The Journal of Rheumatology
Vol. 51, Issue 3
1 Mar 2024
Behçet Syndrome Manifestations and Activity in the United States versus Turkey — A Cross-sectional Cohort Comparison
Cailin Sibley, Yusuf Yazici, Koray Tascilar, Nafiz Khan, Yasmin Bata, Hasan Yazici, Raphaela Goldbach-Mansky, Gulen Hatemi
The Journal of Rheumatology Jun 2014, jrheum.131227; DOI: 10.3899/jrheum.131227
Behçet Syndrome Manifestations and Activity in the United States versus Turkey — A Cross-sectional Cohort Comparison
Cailin Sibley, Yusuf Yazici, Koray Tascilar, Nafiz Khan, Yasmin Bata, Hasan Yazici, Raphaela Goldbach-Mansky, Gulen Hatemi
The Journal of Rheumatology Jun 2014, jrheum.131227; DOI: 10.3899/jrheum.131227